SCHEMBL3626745

SCHEMBL3626745

CC(=O)C1CCC(=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 2/20 0.35
LMNA P02545 2/20 0.34
TSHR P16473 1/20 0.34
TRIM24 O15164 2/20 0.32
TRIM33 Q9UPN9 2/20 0.32
GABRP O00591 2/20 0.31
GABRD O14764 2/20 0.31
GABRA1 P14867 2/20 0.31
GABRB1 P18505 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA5 P31644 2/20 0.31
GABRA3 P34903 2/20 0.31
GABRA2 P47869 2/20 0.31
GABRB2 P47870 2/20 0.31
GABRA4 P48169 2/20 0.31
GABRE P78334 2/20 0.31
GABRA6 Q16445 2/20 0.31
GABRG1 Q8N1C3 2/20 0.31
GABRG3 Q99928 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL4702024 0.95 LMNA (0.36) ESR2LMNATSHRTRPA1
SCHEMBL18951906 0.91 ESR2 (0.39) ESR2LMNATSHRTRIM24TRIM33
SCHEMBL4857880 0.85
SCHEMBL13797790 0.85
SCHEMBL3628643 0.85
SCHEMBL4941703 0.81 ESR2 (0.37) ESR2LMNATSHRTRIM24TRIM33
SCHEMBL28081306 0.78 ESR2 (0.38) ESR2TRIM24TRIM33GABRPGABRD
SCHEMBL13280678 0.77 LMNA (0.37) ESR2LMNATSHRGABRPGABRD
SCHEMBL8486388 0.77 LMNA (0.47) ESR2LMNATSHRTRIM24TRIM33
SCHEMBL13165462 0.76 MAPT (0.38) LMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119524839-A Catalyst for selectively catalyzing hydrogenation of phenol compounds and preparation method thereof 嘉庚创新实验室 2025-02-28 CN claimed
CN-119524839-A Catalyst for selectively catalyzing hydrogenation of phenol compounds and preparation method thereof 嘉庚创新实验室 2025-02-28 CN disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 CN disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
US-20230250110-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-08-10 US disclosed
US-20230183186-A1 PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INCORPORATED 2023-06-15 US disclosed
CN-116082320-A ZESTE enhancer homolog 2 inhibitors and uses thereof 海思科医药集团股份有限公司 2023-05-09 CN disclosed
EP-2735581-B1 COMPOSITION AND POLYMER ASAHI CHEMICAL IND (JP) 2021-07-14 EP disclosed
CN-105754099-B Composition and polymer 旭化成株式会社 2018-09-18 CN disclosed
EP-2611877-B1 METHOD FOR BONDING AND DETACHING WASH-OFF LABELS BASF SE (DE) 2018-06-20 EP disclosed
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds GRUENENTHAL GMBH (DE) 2009-11-19 US disclosed
US-20090111842-A1 SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY GRUENENTHAL GMBH (DE) 2009-04-30 US disclosed
US-20090048323-A1 SUBSTITUTED IMIDAZOLINE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-02-19 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20080102377-A1 rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive UBE INDUSTRIES, LTD (JP) 2008-05-01 US disclosed
CN-101091283-A Nonaqueous electrolytic solution and lithium secondary battery using the same UBE INDUSTRIES (JP) 2007-12-19 CN disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ESR2 928/4885LMNA 2182/4885TSHR 1938/4885
US-20230183186-A1 PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, MC2R ESR2 174/4885LMNA 4762/4885TSHR 216/4885
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors CETP, NPC1, DBI ESR2 2805/4885LMNA 1125/4885TSHR 3907/4885
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R ESR2 1010/4885LMNA 1432/4885TSHR 760/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 ESR2 1935/4885LMNA 2878/4885TSHR 86/4885
US-20090048323-A1 SUBSTITUTED IMIDAZOLINE COMPOUNDS ITCH, OPRK1, ALDH1A1 ESR2 976/4885LMNA 4033/4885TSHR 2305/4885
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same AVPR1B, HRH4, PRLHR ESR2 1033/4885LMNA 4260/4885TSHR 71/4885
US-20090111842-A1 SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY OPRK1, OPRL1, OPRD1 ESR2 852/4885LMNA 1558/4885TSHR 3561/4885
US-20230250110-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ESR2 2856/4885LMNA 1859/4885TSHR 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.